Granulomatose avec polyangéite : quoi de neuf ? [Granulomatosis with polyangiitis: what's new?]

Details

Ressource 1Request a copy Under embargo until 05/10/2024.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_D369BEFFD011
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Granulomatose avec polyangéite : quoi de neuf ? [Granulomatosis with polyangiitis: what's new?]
Journal
Revue medicale suisse
Author(s)
Ringwald M., Chevalley D., Bongard C., Kissling S., Rotman S., Von Garnier C., Ribi C., Comte D.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
05/04/2023
Peer-reviewed
Oui
Volume
19
Number
821
Pages
674-679
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Abstract
Within the group of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides, granulomatosis with polyangiitis (GPA) is the most frequent. The incidence is around 10 to 20 cases/million/year. Clinical manifestations are varied, with ENT, lungs and kidneys most frequently involved. ANCA are pathogenic by triggering neutrophil activation, which leads to vascular damage. Detection of ANCA is most helpful in establishing the diagnosis, but serology may be negative in GPA limited to the airways. Diagnostic work-up and therapy require a multidisciplinary approach. Treatment includes an induction and maintenance phase, combining corticosteroids and immunosuppressive drugs. It aims at limiting the risk of relapses, which is important in GPA, and at reducing corticosteroids toxicity.
Keywords
Humans, Granulomatosis with Polyangiitis/diagnosis, Granulomatosis with Polyangiitis/therapy, Granulomatosis with Polyangiitis/complications, Antibodies, Antineutrophil Cytoplasmic/therapeutic use, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/therapy, Immunosuppressive Agents/therapeutic use, Adrenal Cortex Hormones/therapeutic use
Pubmed
Create date
11/04/2023 17:14
Last modification date
19/07/2023 7:16
Usage data